Stimuli-responsive polymeric nanomaterials for rheumatoid arthritis therapy.

Yingsi Xie, Ruslan G Tuguntaev, Cong Mao, Haoting Chen, Ying Tao, Shixiang Wang, Bin Yang, Weisheng Guo
Author Information
  1. Yingsi Xie: Translational Medicine Center, Key Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences & the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou 510260, China.
  2. Ruslan G Tuguntaev: Translational Medicine Center, Key Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences & the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou 510260, China.
  3. Cong Mao: Translational Medicine Center, Key Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences & the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou 510260, China.
  4. Haoting Chen: Translational Medicine Center, Key Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences & the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou 510260, China.
  5. Ying Tao: Translational Medicine Center, Key Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences & the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou 510260, China.
  6. Shixiang Wang: Department of cardiovascular medicine, the Third Affiliated Hospital, Guangzhou Medical University, Guangzhou 510260, China.
  7. Bin Yang: The Sixth Affiliated Hospital; Department of Biomedical Engineering, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou 511436, China.
  8. Weisheng Guo: Translational Medicine Center, Key Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences & the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou 510260, China.

Abstract

Rheumatoid arthritis (RA) is a long-term inflammatory disease derived from an autoimmune disorder of the synovial membrane. Current therapeutic strategies for RA mainly aim to hamper the macrophages' proliferation and reduce the production of pro-inflammatory cytokines. Therefore, the accumulation of therapeutic agents targeted at the inflammatory site should be a crucial therapeutic strategy. Nowadays, the nanocarrier system incorporated with stimuli-responsive property is being intensively studied, showing the potentially tremendous value of specific therapy. Stimuli-responsive (., pH, temperature, light, redox, and enzyme) polymeric nanomaterials, as an important component of nanoparticulate carriers, have been intensively developed for various diseases treatment. A survey of the literature suggests that the use of targeted nanocarriers to deliver therapeutic agents (nanotherapeutics) in the treatment of inflammatory arthritis remains largely unexplored. The lack of suitable stimuli-sensitive polymeric nanomaterials is one of the limitations. Herein, we provide an overview of drug delivery systems prepared from commonly used stimuli-sensitive polymeric nanomaterials and some inorganic agents that have potential in the treatment of RA. The current situation and challenges are also discussed to stimulate a novel thinking about the development of nanomedicine.

Keywords

References

  1. Macromol Rapid Commun. 2012 May 14;33(9):760-6 [PMID: 22495770]
  2. Nanotechnology. 2013 Jul 12;24(27):275101 [PMID: 23759860]
  3. EMBO J. 1991 Dec;10(13):4025-31 [PMID: 1721867]
  4. J Biol Chem. 2013 May 10;288(19):13410-9 [PMID: 23530046]
  5. ACS Nano. 2019 May 28;13(5):5036-5048 [PMID: 30978282]
  6. JAMA. 2018 Oct 02;320(13):1360-1372 [PMID: 30285183]
  7. Langmuir. 2012 Feb 7;28(5):2327-31 [PMID: 22263885]
  8. Free Radic Biol Med. 2016 Aug;97:285-291 [PMID: 27344969]
  9. ACS Appl Mater Interfaces. 2016 Aug 24;8(33):21107-33 [PMID: 27349465]
  10. Polymers (Basel). 2019 Feb 13;11(2): [PMID: 30960299]
  11. Inflammation. 2015 Feb;38(1):180-6 [PMID: 25240765]
  12. Trends Endocrinol Metab. 2018 Jan;29(1):42-54 [PMID: 29162310]
  13. J Am Chem Soc. 2010 Jul 21;132(28):9540-2 [PMID: 20568765]
  14. J Nanobiotechnology. 2018 Sep 19;16(1):71 [PMID: 30231877]
  15. Langmuir. 2014 Jun 3;30(21):6021-9 [PMID: 24850568]
  16. Biomaterials. 2019 Aug;211:68-80 [PMID: 31096162]
  17. Arthritis Care Res (Hoboken). 2017 Oct;69(10):1467-1472 [PMID: 28388820]
  18. J Immunol. 2009 Jun 15;182(12):7974-81 [PMID: 19494322]
  19. Angew Chem Int Ed Engl. 2011 Sep 26;50(40):9404-8 [PMID: 21898731]
  20. Int J Nanomedicine. 2017 Sep 11;12:6735-6746 [PMID: 28932117]
  21. Small. 2013 Jan 28;9(2):284-93 [PMID: 22930531]
  22. J Control Release. 2017 Apr 28;252:62-72 [PMID: 28288894]
  23. Int J Mol Sci. 2017 Apr 28;18(5): [PMID: 28452928]
  24. Biomacromolecules. 2006 Jan;7(1):64-70 [PMID: 16398499]
  25. Drug Des Devel Ther. 2018 Sep 24;12:3117-3145 [PMID: 30288019]
  26. Molecules. 2019 Mar 21;24(6): [PMID: 30901827]
  27. Biomacromolecules. 2007 Nov;8(11):3401-7 [PMID: 17939711]
  28. Bioconjug Chem. 2003 Mar-Apr;14(2):412-9 [PMID: 12643752]
  29. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011 Nov-Dec;3(6):607-19 [PMID: 21837725]
  30. Expert Opin Drug Deliv. 2009 Jan;6(1):53-70 [PMID: 19236208]
  31. Nat Mater. 2010 Nov;9(11):923-8 [PMID: 20935658]
  32. Expert Opin Ther Pat. 2008 Jul;18(7):723-738 [PMID: 19578469]
  33. Colloids Surf B Biointerfaces. 2011 Oct 15;87(2):454-63 [PMID: 21719259]
  34. Nat Mater. 2013 Nov;12(11):991-1003 [PMID: 24150417]
  35. Adv Drug Deliv Rev. 2013 Jun 15;65(6):865-79 [PMID: 23159541]
  36. Nanomedicine. 2016 May;12(4):1113-1126 [PMID: 26733257]
  37. ACS Nano. 2013 Jan 22;7(1):50-7 [PMID: 23194301]
  38. Nat Nanotechnol. 2019 Nov;14(11):1007-1017 [PMID: 31695150]
  39. Int J Mol Sci. 2018 Jul 06;19(7): [PMID: 29986450]
  40. Best Pract Res Clin Gastroenterol. 2010 Apr;24(2):121-32 [PMID: 20227026]
  41. Immunity. 2017 Feb 21;46(2):183-196 [PMID: 28228278]
  42. Science. 1956 Mar 30;123(3196):527-34 [PMID: 13298712]
  43. Nat Rev Rheumatol. 2012 Mar 13;8(4):235-43 [PMID: 22410633]
  44. Int J Mol Sci. 2016 Aug 31;17(9): [PMID: 27589733]
  45. Iran J Pharm Res. 2017 Fall;16(4):1273-1304 [PMID: 29552041]
  46. Best Pract Res Clin Rheumatol. 2017 Feb;31(1):3-18 [PMID: 29221595]
  47. Int J Pharm. 2009 Dec 1;382(1-2):270-6 [PMID: 19712736]
  48. Nat Rev Dis Primers. 2018 Feb 08;4:18001 [PMID: 29417936]
  49. Pharmaceutics. 2019 Nov 06;11(11): [PMID: 31698794]
  50. Langmuir. 2012 Jun 26;28(25):9413-20 [PMID: 22624601]
  51. J Clin Invest. 1982 Sep;70(3):550-7 [PMID: 7107894]
  52. Nano Lett. 2020 Apr 8;20(4):2558-2568 [PMID: 32167768]
  53. Biomacromolecules. 2010 Aug 9;11(8):1915-20 [PMID: 20690704]
  54. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016 Sep;8(5):696-716 [PMID: 26762467]
  55. Small. 2008 Apr;4(4):421-6 [PMID: 18383576]
  56. Biomaterials. 2011 Aug;32(22):5223-30 [PMID: 21514660]
  57. J Control Release. 2011 May 30;152(1):49-56 [PMID: 21397642]
  58. Lancet. 2017 Jun 10;389(10086):2328-2337 [PMID: 28612747]
  59. Biomacromolecules. 2013 Jun 10;14(6):2074-82 [PMID: 23617223]
  60. Mol Pharm. 2005 Sep-Oct;2(5):357-66 [PMID: 16196488]
  61. Molecules. 2019 Jul 12;24(14): [PMID: 31336916]
  62. Colloids Surf B Biointerfaces. 2018 Oct 1;170:224-232 [PMID: 29929166]
  63. Curr Pharm Des. 2013;19(41):7169-84 [PMID: 23489197]
  64. J Rheumatol. 1989 Apr;16(4):468-72 [PMID: 2746586]
  65. Ann Rheum Dis. 2010 Nov;69(11):1898-906 [PMID: 20959326]
  66. Chem Commun (Camb). 2011 Mar 14;47(10):2826-8 [PMID: 21240412]
  67. Macromolecules. 2011;44(21):8590-8597 [PMID: 22096258]
  68. J Control Release. 2008 Mar 20;126(3):187-204 [PMID: 18261822]
  69. Mol Pharm. 2012 Sep 4;9(9):2554-64 [PMID: 22849291]
  70. Adv Mater. 2011 Oct 18;23(39):4549-53 [PMID: 21910141]
  71. Acta Pharm Sin B. 2014 Apr;4(2):120-7 [PMID: 26579373]
  72. Colloids Surf B Biointerfaces. 2015 Sep 1;133:378-87 [PMID: 25979151]
  73. Adv Healthc Mater. 2014 Apr;3(4):596-608 [PMID: 23983152]
  74. Nat Mater. 2010 Feb;9(2):101-13 [PMID: 20094081]
  75. Molecules. 2019 Jan 02;24(1): [PMID: 30609724]
  76. Int J Nanomedicine. 2019 Mar 06;14:1707-1723 [PMID: 30880975]
  77. Bone Res. 2018 Apr 27;6:15 [PMID: 29736302]
  78. Langmuir. 2012 Jun 26;28(25):9387-94 [PMID: 22646923]
  79. Eur J Pharm Biopharm. 2011 Nov;79(3):526-36 [PMID: 21736940]
  80. Adv Healthc Mater. 2020 Mar;9(6):e1901541 [PMID: 32031759]
  81. Eur J Pharm Biopharm. 2018 Sep;130:39-47 [PMID: 29928978]
  82. Clin Exp Rheumatol. 1985 Apr-Jun;3(2):99-104 [PMID: 4017318]
  83. Dalton Trans. 2010 Nov 28;39(44):10685-91 [PMID: 20938539]
  84. Biomaterials. 2015 Aug;61:95-102 [PMID: 26001074]
  85. Nanotechnology. 2011 Feb 11;22(6):065702 [PMID: 21212480]
  86. Biomacromolecules. 2014 Jul 14;15(7):2583-9 [PMID: 24915286]
  87. Biomacromolecules. 2014 Jan 13;15(1):262-75 [PMID: 24313925]
  88. Oxid Med Cell Longev. 2019 Dec 14;2019:7536805 [PMID: 31934269]
  89. Adv Drug Deliv Rev. 2012 Aug;64(11):967-78 [PMID: 22266127]
  90. Acta Orthop Scand. 1969;40(5):634-41 [PMID: 5378127]

Word Cloud

Created with Highcharts 10.0.0arthritistherapeuticpolymericnanomaterialsRAinflammatoryagentsStimuli-responsivetreatmentRheumatoidtargetedintensivelytherapystimuli-sensitivedeliverysystemslong-termdiseasederivedautoimmunedisordersynovialmembraneCurrentstrategiesmainlyaimhampermacrophages'proliferationreduceproductionpro-inflammatorycytokinesThereforeaccumulationsitecrucialstrategyNowadaysnanocarriersystemincorporatedstimuli-responsivepropertystudiedshowingpotentiallytremendousvaluespecificpHtemperaturelightredoxenzymeimportantcomponentnanoparticulatecarriersdevelopedvariousdiseasessurveyliteraturesuggestsusenanocarriersdelivernanotherapeuticsremainslargelyunexploredlacksuitableonelimitationsHereinprovideoverviewdrugpreparedcommonlyusedinorganicpotentialcurrentsituationchallengesalsodiscussedstimulatenovelthinkingdevelopmentnanomedicinerheumatoidDrugNanotechnologypolymers

Similar Articles

Cited By